April 11, 2019 Clinical Research/Diagn. Product Launch

QIAGEN highlights profile of new QIAstat-Dx Meningitis / Encephalitis panel focused on most prevalent central nervous system pathogens

Hilden, Germany, and Amsterdam, Netherlands, April 11, 2019 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced new data of the QIAstat-Dx Meningitis / Encephalitis panel. The panel is in late stage development and being prepared for CE-IVD commercialization in the second half of 2019 for use on the QIAstat-Dx multiplex syndromic testing... Read more

April 3, 2019 Clinical Research/Diagn. M&A, Partnerships

QIAGEN and LabCorp launch collaboration to provide Day-One access for patients to innovative companion diagnostics at the time of drug approvals

Hilden, Germany, and Germantown, Maryland, April 03, 2019 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a master service agreement with LabCorp® (NYSE: LH) to further accelerate the access of cancer patients to QIAGEN’s companion diagnostic products following regulatory approvals of drugs and their associated tests. As a new participant in QIAGEN’s... Read more

March 28, 2019 Atomic Spectroscopy Life Science Tools Product Launch

QIAGEN launches novel liquid biopsy solutions and NGS panels with seamlessly integrated bioinformatics to support advances in cancer research

Germantown, Maryland, and Hilden, Germany, March 28, 2019 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of new solutions designed to advance cancer research as part of its highlights at the American Association for Cancer Research (AACR) 2019 Annual Meeting from March 29 to April 3, 2019, in Atlanta, Georgia. More... Read more

March 24, 2019 Liq. Handling & Robotics

QIAGEN supports World TB Day with major innovations in the fight against latent tuberculosis

Hilden, Germany, and Germantown, Maryland, March 24, 2019 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) recognized the annual World TB Day 2019 held on March 24 by highlighting its growing global commitment to preventive screening and treatment for latent tuberculosis (TB) infection, a widespread condition that can lead to active TB disease in... Read more

March 8, 2019 Liq. Handling & Robotics M&A, Partnerships

QIAGEN and Tecan announce collaboration to streamline preanalytical processing of QuantiFERON-TB Gold Plus

Germantown, Maryland, Hilden, Germany, and Männedorf, Switzerland, March 08, 2019 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) and Tecan Group AG (SIX Swiss Exchange: TECN), a global leader in laboratory automation and liquid handling technology, announced today a collaboration to improve the processing of QIAGEN’s QuantiFERON-TB Gold Plus (QFT-Plus) diagnostic test through the... Read more

March 6, 2019 PR/Corporate

QIAGEN announces 20-F annual report filing for 2018 results

Germantown, Maryland, and Hilden, Germany, March 6, 2019 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended December 31, 2018, with the U.S. Securities and Exchange Commission. The document can be accessed on... Read more

February 17, 2019 M&A, Partnerships

QIAGEN partners with Ares Genetics to advance global fight against antibiotic-resistant pathogens

Hilden, Germany, Holzgerlingen, Germany, and Vienna, Austria, February 18, 2019 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a broad agreement with Ares Genetics, a subsidiary of Curetis N.V. (Euronext: CURE), to develop innovative bioinformatics and assay solutions to accelerate research targeting the growing global health challenges posed by antibiotic-resistant bacteria. QIAGEN... Read more

February 4, 2019 Life Science Tools M&A, Partnerships

QIAGEN informatics solutions chosen to support Genomics England’s bold five million genomes in five years project

Hilden, Germany, and London, United Kingdom, February 4, 2019 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that Genomics England have selected QIAGEN’s QCI (QIAGEN Clinical Insights) portfolio offering on behalf of the NHS in England to support the UK’s program to sequence, analysis and interpret 5 million genomes over the next 5... Read more

January 16, 2019 Clinical Research/Diagn. PR/Corporate

QIAGEN receives approval for EGFR test in lung cancer as companion diagnostic in Japan

Hilden, Germany, and Tokyo, Japan, January 16, 2019 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that the Japanese Pharmaceuticals and Medical Device Agency (PMDA) has approved the therascreen® EGFR RGQ PCR Kit to allow its use as a companion diagnostic with Pfizer’s VIZIMPRO® (dacomitinib) for EGFR gene mutation-positive, inoperable or recurrent... Read more